TREAT-TO-TARGET MAINTENANCE EFFICACY AND PHARMACOKINETICS OF USTEKINUMAB DOSING REGIMEN UP TO WEEK 48 IN THE STARDUST TRIAL

Geert R. D'Haens  ¹     Silvio Danese  ²     Severine Vermeire  ³     Julian Panés  ⁴     Axel Dignass  ⁵     Fernando Magro  ⁶     Maciej Nazar  ⁷     Manuela Le Bars  ⁸     Marjolein Lahaye  ⁹     Lioudmila Ni  ¹⁰     Ivana Bravatà  ¹¹     Omoniyi J. Adedokun  ¹²     Daniel R. Gaya  ¹³     Laurent Peyrin-Biroulet  ^14    
1 Academic Medical Center, Amsterdam, Netherlands
² IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milan, Italy
³ University Hospitals Leuven, Leuven, Belgium
⁴ Hospital Clinic of Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain
⁵ Agaplesion Markus Hospital, Frankfurt/ Main, Germany
⁶ Institute for Molecular and Cell Biology, Faculty of Medicine University of Porto, Porto, Portugal
⁷ Janssen-Cilag Polska Sp. z .o.o., Warsaw, Poland
⁸ Janssen-Cilag, Issy-Les-Moulineaux, France
⁹ Janssen-Cilag BV, Breda, Netherlands
¹⁰ Janssen-Cilag Russia, Moscow, Russian Federation
¹¹ Janssen-Cilag, Milan, Italy
¹² Janssen Research & Development, LLC., Spring House, Pennsylvania
¹³ Glasgow Royal Infirmary, Glasgow, United Kingdom
¹⁴ University Hospital of Nancy, University of Lorraine, Houdemont, France

Topic
IBD, Nurses

Session
Treatment strategies in IBD

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)